Figure 7b:

Hyperprogressive disease in a 64-year-old woman with stage IV non–small cell lung cancer treated with nivolumab. (a) CT image of the abdomen obtained 2.5 months before the initiation of nivolumab therapy shows metastatic liver lesions (arrow). (b) Baseline CT image obtained immediately before the initiation of nivolumab therapy shows a moderate increase in the liver lesion (arrow) compared with a. (c) Initial follow-up CT image obtained after 2 months of nivolumab therapy shows a rapid and marked increase in the existing liver mestastasis (arrow), as well as the appearance of immunerable new liver lesions occupying majority of liver parenchyma in both lobes, indicating hyperprogressive disease on nivolumab therapy.